Treatment of chronic hepatitis B

Rohit Loomba, T. Jake Liang

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease and hepatocellular carcinoma worldwide. Approximately 350 million individuals are infected with HBV and >500,000 deaths per year can be attributed to HBV. Although universal vaccination has reduced HBV incidence in many countries, it still remains a major public health problem, especially in parts of Asia and Africa. Improved understanding of HBV virology and virus-host interactions has revolutionized chronic hepatitis B therapy in the past two decades. Development of oral nucleoside/nucleotide analogues heralds a new era of safe and effective treatment of this disease. On the basis of these advances, new guidelines for the treatment of chronic hepatitis B have been issued. Successful long-term treatment of chronic hepatitis B may rest on combination therapy that is based on molecular approaches targeting various stages of the HBV life-cycle. In this review, we summarize the current modalities and highlight important issues in the treatment of chronic hepatitis B monoinfection.

Original languageEnglish (US)
JournalAntiviral Therapy
Issue numberSUPPL. 3
StatePublished - 2007
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Treatment of chronic hepatitis B'. Together they form a unique fingerprint.

Cite this